Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R) Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustibe has on subject and subjects lymphoma compared to rituximab plus bendamustine alone, and to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide plus rituximab has on subject and subjects lymphoma compared to continuing treatment with rituximab alone.
Description
The purpose of this study is to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustibe has on subject and subjects lymphoma compared to rituximab plus bendamustine alone, and to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide plus rituximab has on subject and subjects lymphoma compared to continuing treatment with rituximab alone.
Details
| Condition | lymphoma |
|---|---|
| Age | 60years - 100years |
| Clinical Study Identifier | TX4953 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.